A patent settlement can look perfectly clean on its face and still carry antitrust risk buried in its economics. That is the lesson from an $885 million jury verdict handed down in Boston this month, where Takeda was found liable for effectively paying a generic rival to keep its version of the IBS drug Amitiza off the market. There was no cheque labelled “reverse payment.” Instead, the plaintiffs pointed to the structure of the deal — a 50% royalty that dropped to 15% if a second generic entered, and to zero with a third — and argued it gave Takeda every commercial reason not to launch its own authorised generic. The jury agreed, finding an implicit “no-AG” agreement and a large, unjustified payment under the Actavis rule of reason. It is the first time private plaintiffs have taken a pay-for-delay case all the way to a jury and won, and the damages could treble to roughly $2.5 billion.
How you transfer value matters as much as whether you transfer it. Courts and juries will read the commercial logic of a settlement, not just its wording — and an arrangement engineered to suppress competition will be treated as exactly that, however carefully it is drafted.
Tie any agreed entry date to a genuine, documented assessment of patent strength. Scrutinise royalty schedules, authorised-generic rights and every other lever for incentives that look exclusionary in hindsight. And note the timeline: a 2014 deal was still being unwound in 2026 — settlement decisions have a very long risk period. Strong IP strategy isn’t only about owning strong patents. It’s about structuring the deals around them so the economics tell the same story as the paperwork.
Katten’s analysis of the verdict: https://katten.com/lessons-from-landmark-jury-verdict-in-amitiza-reverse-payment-antitrust-case — and the reporting from FiercePharma: https://www.fiercepharma.com/pharma/takeda-slapped-885m-verdict-pay-delay-antitrust-case